Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Comparing the Efficacy and Safety of Biphasic Insulin Aspart 30 and Biphasic Human Insulin 30 on Blood Sugar Control in Subjects With Type 2 Diabetes
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-12-11
- Last Posted Date
- 2015-03-04
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 145
- Registration Number
- NCT00807092
A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Thailand
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-12-10
- Last Posted Date
- 2016-11-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 2342
- Registration Number
- NCT00805922
- Locations
- 🇹🇭
Novo Nordisk Investigational Site, Bangkok, Thailand
Comparison of Efficacy and Safety of Repaglinide Combined With Insulin NPH Versus Biphasic Human Insulin 30 Alone in Inadequately Controlled Subjects With Type 2 Diabetes
Phase 4
Terminated
- Conditions
- First Posted Date
- 2008-11-27
- Last Posted Date
- 2017-02-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 40
- Registration Number
- NCT00799448
- Locations
- 🇬🇷
Novo Nordisk Investigational Site, Athens, Greece
Comparison of the Change in Fat Distribution in Overweight and Obese Subjects With Type 2 Diabetes After Insulin Treatment
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-11-21
- Last Posted Date
- 2016-03-16
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 60
- Registration Number
- NCT00795600
Observational Study to Observe the Efficacy of Levemir® (Insulin Detemir) in Patients With Type 2 Diabetes.
- First Posted Date
- 2008-11-19
- Last Posted Date
- 2014-08-15
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1074
- Registration Number
- NCT00793273
Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetics Failing on OADs
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-11-17
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 102
- Registration Number
- NCT00791895
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Milwaukee, Wisconsin, United States
An Observational Study to Compare the Safety and Effectiveness of NovoMix® 30 and Levemir™ for the Treatment of Diabetes
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-11-13
- Last Posted Date
- 2016-10-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 3131
- Registration Number
- NCT00789711
- Locations
- 🇵🇭
Novo Nordisk Investigational Site, Manilla, Philippines
A Survey to Evaluate Diabetes Management, Control, Chronic Complications, Psychosocial Aspects of Diabetic Subjects in Indonesia
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-11-11
- Last Posted Date
- 2014-06-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1832
- Registration Number
- NCT00788853
Effect of Detemir and Sitagliptin on Blood Glucose Control in Type 2 Diabetes
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-11-11
- Last Posted Date
- 2017-03-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 222
- Registration Number
- NCT00789191
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Kocaeli, Turkey
Long Term Metabolic Safety of Norditropin® Treatment of Small for Gestational Age (SGA) Subjects
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-11-10
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 153
- Registration Number
- NCT00787878
- Locations
- 🇳🇱
Novo Nordisk Investigational Site, Rotterdam, Netherlands
© Copyright 2024. All Rights Reserved by MedPath